You just read:

Biohaven Showcases Positive Data on Rimegepant, Oral CGRP Receptor Antagonist, with 16 Presentations at 2019 American Headache Society (AHS) Annual Scientific Meeting Demonstrating Efficacy in Multiple Patient Types and Long-term Safety

News provided by

Biohaven Pharmaceutical Holding Company Ltd.

Jul 11, 2019, 07:30 ET